Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)

BACKGROUND: It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab. METHODS: In this multicenter randomized phase II trial, all enrolled patients (pts) with T2–T4d HER2-positive BC received 3 cycles of neoadjuvant treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrino, Benedetta, Tommasi, Chiara, Serra, Olga, Gori, Stefania, Cretella, Elisabetta, Ambroggi, Massimo, Frassoldati, Antonio, Bisagni, Giancarlo, Casarini, Chiara, Bria, Emilio, Carbognin, Luisa, Fiorio, Elena, Mura, Antonella, Zamagni, Claudio, Gianni, Lorenzo, Zambelli, Alberto, Montemurro, Filippo, Tognetto, Michele, Todeschini, Renata, Missale, Gabriele, Campanini, Nicoletta, Silini, Enrico Maria, Maglietta, Giuseppe, Musolino, Antonino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685938/
https://www.ncbi.nlm.nih.gov/pubmed/38016718
http://dx.doi.org/10.1136/jitc-2023-007667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685938/
https://www.ncbi.nlm.nih.gov/pubmed/38016718
http://dx.doi.org/10.1136/jitc-2023-007667

Ejemplares similares